Organization
Hospital 12 de Octubre
8 abstracts
1 poster
Abstract
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).Org: Dana-Farber Cancer Institute, Medical Faculty Mannheim, Pangaea Oncology, Queen Mary University of London, Centre Léon Bérard,
Abstract
ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma.Org: Medical Oncology Department, Institute of Biomedicine of Seville, Hospital Universitario y Politécnico La Fe, Son Espases University Hospital, University Hospital Virgen del Rocio,
Abstract
Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.Org: SOLTI Cancer Research Group, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Vall d’Hebron Institute of Oncology,
Abstract
Development of a multiparametric prognostic score based on PAM50, in patients with HR+/HER2- advanced breast cancer (aBC) treated with endocrine therapy (ET) plus cyclin dependent kinase 4 and 6 inhibitors (CDKi), within the CDK-PREDICT (SOLTI-1801) study and HCB cohort.Org: SOLTI Cancer Research Group, August Pi i Sunyer Biomedical Research Institute, Hospital Clínic de Barcelona, IDIBAPS, Biomedical Research Institute INCLIVA, Hospital Universitario 12 de Octubre Research Institute,
Abstract
Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital 12 de Octubre, Hospital Clínic de Barcelona, IDIBAPS, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), SOLTI Breast Cancer Cooperative Group,
Abstract
Progression-free survival as a surrogate endpoint of overall survival in advanced biliary tract cancer: A meta-analysis of randomized trials and individual-patient level correlation.Org: Vall d'Hebron Institute of Oncology, UGC Oncología Guipúzcoa, Hospital 12 de Octubre, Hospital Universitario Central de Asturias, Hospital Universitario Gregorio Marañón,
Abstract
Clinical utility of a novel non-invasive technology for monitoring severe neutropenia in anticancer therapy.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital 12 de Octubre, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Hematology Department, Hospital Universitari i Politècnic La Fe, Boston Medical Center,
Abstract
ABATACEPT IN RHEUMATOID ARTHRITIS WITH INTERSTITIAL LUNG DISEASE: A MULTICENTRE STUDY IN 34 PATIENTS Org: Hospital Universitario Marques de Valdecilla, Clinic Hospital Santiago de Compostela, Hospital la Princesa, Hospital Puerta del Hierro, Hospital 12 de Octubre,